| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Arrowhead Pharmaceuticals, Inc. (ARWR) has 12 insiders with recent SEC Form 4 filings, including 3 buys and 14 sells. ARWR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.79M | $311.82M | - | |
| COO | 473.3K | $38.91M | - | |
| Other | 227.0K | $18.66M | - | |
| CFO | 162.9K | $13.39M | - | |
| Dir | 123.1K | $10.12M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Anzalone Christopher Richard60 | Chief Executive Officer | Sell | 26,712 | $21.24 | $567,485.84 | -0.2% | -25.9% | +226.5% | |
| Dec 17, 2024 | Given Douglas B66 | Director | Sell | 5,547 | $21.91 | $121,555.88 | -2.2% | -30.0% | +191.0% | |
| Dec 17, 2024 | Waddill William D.50 | Director | Sell | 7,495 | $21.97 | $164,665.08 | -8.1% | -30.0% | +191.0% | |
| Dec 16, 2024 | Vakiener Victoria53 | Director | Sell | 8,994 | $21.91 | $197,058.54 | -29.8% | -30.3% | +189.0% | |
| Jul 2, 2024 | Oliver Tracie70 | Chief Commercial Officer | Sell | 9,394 | $25.28 | $237,480.32 | -6.9% | -23.2% | -33.0% | |
| May 2, 2024 | Vakiener Victoria53 | Director | Sell | 1,799 | $23.31 | $41,934.69 | -5.6% | +18.4% | -40.2% | |
| Apr 1, 2024 | Hamilton James C72 | Chief Discovery/ Trans Medicine | Sell | 6,000 | $28.03 | $168,180.00 | -2.8% | -7.8% | -56.8% | |
| Mar 20, 2024 | Lu Hongbo59 | Director | Buy | 3,000 | $27.66 | $82,990.00 | +3.2% | -16.3% | -46.3% | |
| Mar 6, 2024 | Myszkowski Kenneth Allen68 | Chief Financial Officer | Sell | 40,000 | $35.19 | $1,407,600.00 | -9.1% | -28.6% | -50.1% | |
| Jan 31, 2024 | Anzalone Christopher Richard60 | Chief Executive Officer | Sale+OE | 57,499 | $32.35 | $1,860,019.34 | -0.8% | -29.5% | -37.0% |